Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Positive Technologies shareholders to discuss additional share issue

6/7/24 POSI

Board of Directors of Rushydro recommended that dividends be paid for 2023

6/7/24 HYDR

Rusagro will build a rapeseed and oil plant in Kuzbass

6/7/24 AGRO

TMK sold Yartsevsky Metzavod

6/7/24 TRMK

Sovcombank to pay for 90% of Home Bank through additional share issue

6/7/24 SVCB

Shareholders of Samaraenergo approved dividends for 2023

6/7/24 SAGO

Medsi may IPO before the end of the year

6/7/24 AFKS

Lukoil restored the Nizhny Novgorod Refinery

6/7/24 LKOH

Element will develop power electronics together with LETI

6/7/24 ELMT

RuStore audience approached 40 mln users per month

6/7/24 VKCO